​​Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas​ 

“The strategy to engage the immune system with a specific T‑cell engager and deliver a potent cytotoxic payload with a DLL3‑targeting ADC, aligns with our immuno‑oncology strategy and our drive to advance smart combinations for hard‑to‑treat cancers,” said Itziar Canamasas, Ph.D., Global Head of Oncology at Boehringer Ingelheim. “It’s another step in our mission to expand effective options for people with DLL3‑expressing cancers.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib